Asia-Pacific Bladder Cancer Market Size, Industry Trends, Share and Forecast 2020-2026

1. Asia-Pacific bladder cancer market is estimated to grow at a CAGR of around 9.7% during the forecast period. The growing number of smokers in Asian economies is one of the major factors attributing to the increasing number of bladder cancer patients. The number of smokers is increasing substantially in the adult population of the region due to the changing lifestyle and shifting habits towards smoking and tobacco consumption. Other factors that are considered as the significant cause of bladder cancer include radiation exposure, intake, or exposure to hazardous chemicals, aging, and others. Aging is considered as the major factors leading to bladder cancer due to the weakening of immune cells against cancer tissues in the bladder. Countries of Asia-Pacific such as Japan and China are reported to the aging population rapidly. Therefore, Asia-Pacific is comparatively more prone to bladder cancer as compared to other regions. Get Free Sample Copy @ https://www.omrglobal.com/request-sample/japan-bladder- cancer-market Asia-Pacific bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The chemotherapy is highly adopted as it kills cancer cells that are spread to other parts of the body, far from its primary tumor. Browse for Full Report at: https://www.omrglobal.com/industry-reports/japan-bladder- cancer-market 5. Market Segmentation 5.1. Asia-Pacific Bladder Cancer Market by Cancer Type 5.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma 5.1.2. Squamous Cell Bladder Cancer

2. 5.1.3. Adenocarcinoma 5.1.4. Others (Sarcomas, Carcinoma in Situ) 5.2. Asia-Pacific Bladder Cancer Market by Diagnosis 5.2.1. Cystoscopy 5.2.2. Biopsy 5.2.3. Urinalysis 5.2.4. Urine Cytology 5.2.5. Intravenous Pyelogram (IVP) 5.2.6. Others (Biomarkers) 5.3. Asia-Pacific Bladder Cancer Market by Treatment 5.3.1. Surgery 5.3.2. Chemotherapy 5.3.3. Immunotherapy 5.3.4. Radiation Therapy 5.3.5. Others (Targeted Therapy) 6. Regional Analysis 6.1. China 6.2. Japan 6.3. India 6.4. Rest of Asia-Pacific

3. 7. Company Profiles 7.1. Astellas Pharma Inc. 7.2. AstraZeneca PLC 7.3. Bayer AG 7.4. Bristol-Myers Squibb Co. 7.5. Eli Lilly and Co. 7.6. F. Hoffmann-La Roche Ltd. 7.7. GlaxoSmithKline Plc 7.8. Johnson & Johnson Services, Inc. 7.9. Merck KGaA 7.10. Pfizer Inc. 7.11. Sysmex Corp. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-bladder-cancer-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404